Related Experiment Video

Updated: May 21, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model

Vincenzo Cuccurullo, Luigi Mansi

    European Journal of Nuclear Medicine and Molecular Imaging
    |May 31, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
    10:13

    Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

    Published on: August 12, 2014

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
    08:52

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

    Published on: November 22, 2021

    Related Experiment Videos

    Last Updated: May 21, 2026

    Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
    09:24

    Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

    Published on: June 9, 2016

    Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
    10:13

    Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

    Published on: August 12, 2014

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
    08:52

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

    Published on: November 22, 2021

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

    Articles linked to this work by shared authors, journal, and citation graph.

    Can we now save the neck of OSCC T1-T2 patients? A narrative review of whether experimental techniques are on the way to clinical application.

    Exploration of targeted anti-tumor therapy·2026

    AI-assisted Decision-support Framework for Breast Density and Background Parenchymal Enhancement Assessment in Contrast-enhanced Mammography.

    Current medical imaging·2026

    Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.

    Cancers·2026

    Imaging Immunotherapy.

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

    Investigating the Performance of X-ray Protection of Various Elements and Alloy Compounds in Aprons for Interventional Radiology.

    Advanced biomedical research·2026

    Beyond Cancer Detection: An AI Framework for Multidimensional Risk Profiling on Contrast-Enhanced Mammography.

    Diagnostics (Basel, Switzerland)·2025

    ¹⁸F-sodium fluoride PET/CT as a complementary measure of osteoblastic disease burden in axial spondyloarthritis: a prospective exploratory study.

    European journal of nuclear medicine and molecular imaging·2026

    First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT.

    European journal of nuclear medicine and molecular imaging·2026

    Diagnostic performance of multiparametric model integrating ¹⁸F-MFBG PET/CT imaging parameters and clinical factors for differentiating neuroblastoma from ganglioneuroblastoma: a preliminary study.

    European journal of nuclear medicine and molecular imaging·2026

    PD-L1 PET/CT imaging with 18F-BMS-986,229 and 18F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer.

    European journal of nuclear medicine and molecular imaging·2026

    A FABulous approach to image human macrophages.

    European journal of nuclear medicine and molecular imaging·2026

    Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease.

    European journal of nuclear medicine and molecular imaging·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us